Clinical Research Directory
Browse clinical research sites, groups, and studies.
SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial
Sponsor: Massachusetts General Hospital
Summary
SAVE-Care (Sodium Glucose Cotransporter-2 inhibitors \[SGLT2i\] As Novel Gout Care) Trial is a double-blind randomized placebo-controlled trial (RCT) designed to assess the effect of empagliflozin on serum urate \[SU\] levels of gout patients, as well as levels of highly-sensitivity C-reactive protein \[hsCRP\] and interleukin 6 \[IL-6\], and estimate gout flares over 3 months, in order to develop a full-scale RCT of clinical endpoints to directly inform gout care guidelines.
Official title: SAVE-Care (SGLT2i As Novel Gout Care) Trial
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-04-30
Completion Date
2028-02-28
Last Updated
2026-03-30
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin 10 mg
For the empagliflozin arm, participants will take 10 mg daily.
Placebo
Participants in the placebo arm will take a placebo daily.